Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

5-LO inhibitor under evaluation at SKB

Dec. 19, 1996

Dual-action compounds claimed by British Biotech

Dec. 17, 1996

Antiallergic/antiasthmatic compounds disclosed by Dainippon Ink

Dec. 16, 1996

New antitussive agent from Snow Brand Milk Products

Dec. 16, 1996

5-LO inhibitor approved by FDA

Dec. 13, 1996

Abbott reports on new PAF antagonists

Dec. 13, 1996

NK1 antagonists described by Boehringer Ingelheim

Dec. 13, 1996

Daiichi claims LTD4 antagonists for treating allergic diseases

Dec. 12, 1996

HMR describes NK1/NK2 antagonists for respiratory indications

Dec. 11, 1996

Japanese researchers disclose substance P antagonists

Dec. 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.